Combination therapy using c-Met inhibitor and beta-catenin inhibitor
A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
1. A method of combination therapy for treating a cancer comprising co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject with cancer.
2. The method of claim 1 , wherein the c-Met inhibitor comprises at least one selected from the group consisting of an anti-c-Met antibody or an antigen-binding fragment thereof, an aptamer, siRNA, shRNA, microRNA, a small molecule c-Met inhibitor against c-Met protein or a gene encoding the c-Met protein, pharmaceutically acceptable salts thereof, and combinations thereof.
3. The method of claim 2 , wherein the c-Met inhibitor comprises an anti-c-Met antibody or antigen binding fragment thereof, and the anti-c-Met antibody or antigen binding fragment thereof specifically binds to an epitope comprising 5 to 19 consecutive amino acids of SEQ ID NO: 71 including SEQ ID NO: 73.
4. The method of claim 2 , wherein the c-Met inhibitor comprises an anti-c-Met antibody or antigen binding fragment thereof, and the anti-c-Met antibody or an antigen-binding fragment thereof comprises:
a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 2, or comprising an amino acid sequence of 8 to 19 consecutive amino acids within SEQ ID NO: 2 including the 3 rd to 10 th positions of SEQ ID NO: 2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 85, or comprising an amino acid sequence of 6 to 13 consecutive amino acids within SEQ ID NO: 85 including the 1 st to 6 th positions of SEQ ID NO: 85;
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 86, SEQ ID NO: 89, or 9 to 17 consecutive amino acids within SEQ ID NO: 89 including the 1 st to 9 th positions of SEQ ID NO: 89.
5. The method of claim 4 , wherein the anti-c-Met antibody or an antigen-binding fragment thereof comprises:
a heavy chain variable region comprising
a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 22, 23, and 24,
a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 25, and 26, and
a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 27, 28, and 85; and
a light chain variable region comprising
a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 29, 30, 31, 32, 33, and 106,
a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 34, 35, and 36, and
a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15, 16, 37, 86, and 89.
6. The method of claim 4 , wherein anti-c-Met antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, 74, 87, 90, 91, 92, 93, or 94, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, 107 or 132, or a combination thereof.
7. The method of claim 4 , wherein the anti-c-Met antibody comprises:
a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, the amino acid sequence of the 18 th to 462 nd positions of SEQ ID NO: 62, the amino acid sequence of the 18 th to 461 st positions of SEQ ID NO: 64, and the amino acid sequence of the 18 th to 460 th positions of SEQ ID NO: 66; and
a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 108, the amino acid sequence of the 21 st to 240 th positions of SEQ ID NO: 68, and the amino acid sequence of the 21 st to 240 th positions of SEQ ID NO: 70.
8. The method of claim 7 , wherein the anti-c-Met antibody comprises a heavy chain comprising the amino acid sequence of the 18 th to 460 th positions of SEQ ID NO: 66; and a light chain comprising the amino acid sequence of the 21 st to 240 th positions of SEQ ID NO: 68.
9. The method of claim 2 , wherein the c-Met inhibitor comprises an anti-c-Met antibody or antigen binding fragment thereof, and the anti-c-Met antibody comprises a heavy chain comprising SEQ ID NO: 109 or 111; and a light chain comprising SEQ ID NO: 110 or 112.
10. The method of claim 2 , wherein the c-Met inhibitor comprises crizotinib, cabozantinib, foretinib, PHA-665752, SU11274, SGX-523, PF-04217903, EMD 1214063, Golvatinib, INCB28060, MK-2461, tivantinib, NVP-BVU972, AMG458, BMS 794833, BMS 777607, MGCD-265, AMG-208, BMS-754807, JNJ-38877605, or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the beta-catenin inhibitor comprises an anti-beta-catenin antibody or an antigen-binding fragment thereof; an aptamer, siRNA, shRNA, microRNA, or small molecule inhibitor of beta-catenin protein or a gene encoding the beta-catenin protein; a pharmaceutically acceptable salt thereof; or a combination thereof.
12. The method of claim 11 , wherein the beta-catenin inhibitor comprises XAV-939, imatinib, ICG-001, IWP-2, IWR-1-endo, KY02111, Wnt-059, IWR-1-exo, FH535, Cardinonogen 1, CCT 031374 hydrobromide, or a pharmaceutically acceptable salt thereof; or siRNA comprising a sense strand comprising one of SEQ ID NOs: 113 to 127.
13. The method of claim 1 , wherein the cancer is an anti-c-Met inhibitor-resistant cancer.
14. The method of claim 1 , wherein the cancer is squamous cell carcinoma, small-cell lung cancer, non-small-cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal carcinoma, skin cancer, melanoma in the skin or eyeball, rectal cancer, cancer near the anus, esophagus cancer, small intestinal tumor, endocrine gland cancer, parathyroid cancer, adrenal cancer, soft-tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular adenoma, breast cancer, colon cancer, large intestine cancer, endometrial carcinoma or uterine carcinoma, salivary gland tumor, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancers, brain cancer, or osteosarcoma.
15. The method of claim 14 , wherein the cancer is colon cancer, breast cancer, or kidney cancer.
16. A method for improving the efficacy of a c-Met inhibitor, comprising administering a beta-catenin inhibitor together with the c-Met inhibitor to a subject with cancer.
17. A method for improving the efficacy of a beta-catenin inhibitor, comprising administering a c-Met inhibitor together with the beta-catenin inhibitor to a subject with cancer.
18. A pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor.
19. A kit comprising a first pharmaceutical composition comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, a second pharmaceutical composition comprising a pharmaceutically effective amount of a beta-catenin inhibitor as an active ingredient, and a package container containing the first and second pharmaceutical compositions.